Back to search

NANO2021-Nanoteknologi og nye materiale

Development of new technology to reduce unwanted uptake of large molecule compounds and nano formulations in liver

Alternative title: Utvikling av ny teknologi for å redusere uønsket opptak av makromolekylære legemidler og nanoformulasjoner i lever.

Awarded: NOK 0.38 mill.

Project Number:

269037

Project Period:

2017 - 2019

Organisation:

Subject Fields:

Partner countries:

The past century has seen the development of medications enabling treatment of more and more diseases. Yet, there are several diseases that present day therapeutics is unable to remedy. Examples of such diseases are several types of cancer, many viral infections, and genetically caused metabolic diseases. In recent years a new class of pharmaceuticals have emerged, aiming to cure these difficult-to-treat diseases. Comprising large molecule compounds (e.g. oligonucleotides that control the synthesis of certain proteins in cells, enzymes that supply lack of specific enzymes, or antibodies that carry toxic compounds to cancer cells) these new generation drugs differ from the classical ones by their higher molecular size and their modes of administration. Several of these drugs have to be administered intravenously to reach their target cells. Hence, the devlopment of these drugs includes efforts to control their delivery. Due to the very high ability of the liver to recognize and take up foreign substances from the blood circulation, a major challenge for developers of this new generation of drugs is their rapid and high capacity uptake in liver. Hence, considerable resources have been spent to circumvent the liver uptake of these compounds. This has proven to be extremely difficult. We here propose a new technology to reduce this unwanted liver uptake of large molecule compounds and nanoparticle formulations. A successful development of our innovation will contribute to remedy several diseases for which no cure exists. Hence, the potential for profit by developing our idea is enormous.

-

The international biopharmaceutical industry has over the last years greatly accelerated the development of large molecule compounds and nanoparticle formulations. One of the largest barriers seriously slowing the development of this category of drug candidates is unwanted uptake in liver. We here propose a new technology to reduce this unwanted liver uptake. A successful development of our innovation will contribute to remedy several diseases for which no cure exists. Hence, the potential for profit by developing our idea is enormous.

Funding scheme:

NANO2021-Nanoteknologi og nye materiale